Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Lisa H. Morrissey"'
Autor:
F. Anthony Greco, Lisa H. Morrissey, Matthew J. McCarty, Sharlene Litchy, Michael B. Andrews, John D. Hainsworth, Manuel Grimaldi
Publikováno v:
Journal of Clinical Oncology. 23:1500-1506
Purpose To evaluate the feasibility and efficacy of rituximab with short-duration chemotherapy in the first-line treatment of patients with follicular non-Hodgkin’s lymphoma (NHL). Patients and Methods Patients with previously untreated stage II-IV
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03008ebd67c4e651aaab5701419e2d8d
https://doi.org/10.1200/jco.2005.05.004
https://doi.org/10.1200/jco.2005.05.004
Autor:
F. Anthony Greco, Lisa H. Morrissey, Denise A. Yardley, Howard A. Burris, Steven W. Corso, Daniel C. Scullin, Sharlene Litchy, John D. Hainsworth
Publikováno v:
Journal of Clinical Oncology. 20:4261-4267
PURPOSE: To evaluate response to single-agent rituximab in patients with indolent non-Hodgkin’s lymphoma (NHL) and no previous systemic therapy, and the feasibility, toxicity, and efficacy of maintenance rituximab, administered at 6-month intervals
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba7bc291da7213c8a4cf8ac2fbc058c9
https://doi.org/10.1200/jco.2002.08.674
https://doi.org/10.1200/jco.2002.08.674
Autor:
J. R. Gray, F. Anthony Greco, John D. Hainsworth, L A Kalman, Jeremy K. Hon, Lisa H. Morrissey
Publikováno v:
Journal of Clinical Oncology. 20:2937-2942
PURPOSE: To provide long-term follow-up on the survival of patients with advanced non–small-cell lung cancer treated with paclitaxel/carboplatin-based regimens in a multicenter, community-based setting. PATIENTS AND METHODS: Between March 1995 and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f7332352ab0ca831a3f4c05b6b481f3
https://doi.org/10.1200/jco.2002.10.071
https://doi.org/10.1200/jco.2002.10.071
Autor:
Lisa H. Morrissey, John H. Barton, Sharlene Litchy, Daniel C. Scullin, John D. Hainsworth, Howard A. Burris, Joan B. Erland, Paul Richards, F. Anthony Greco, James E. Bradof
Publikováno v:
Journal of Clinical Oncology. 20:1651-1656
PURPOSE: To evaluate the efficacy and toxicity of the novel chemotherapy combination that includes gemcitabine, carboplatin, and paclitaxel in the treatment of patients with carcinoma of unknown primary site. PATIENTS AND METHODS: One hundred twenty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3313f85212549dd168c9f2f5869193c
https://doi.org/10.1200/jco.2002.20.6.1651
https://doi.org/10.1200/jco.2002.20.6.1651
Autor:
Howard A. Burris, Lisa H. Morrissey, Ronald G. Steis, A. A. Meluch, John D. Hainsworth, F. Anthony Greco, Valerie Johnson, Timothy J. O'Rourke, Gregory L. Ortega
Publikováno v:
Journal of Clinical Oncology. 19:3018-3024
PURPOSE: To evaluate the toxicity and efficacy of combination chemotherapy with paclitaxel and gemcitabine in patients with advanced transitional-cell carcinoma of the urothelial tract. PATIENTS AND METHODS: Fifty-four patients with advanced unresect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::301a020be68723ba8847d1fd522ebd81
https://doi.org/10.1200/jco.2001.19.12.3018
https://doi.org/10.1200/jco.2001.19.12.3018
Autor:
Lisa H. Morrissey, A. A. Meluch, John D. Hainsworth, F. Anthony Greco, Margaret N. Baker, Howard A. Burris
Publikováno v:
Cancer. 92:642-649
BACKGROUND The purpose of this study was to evaluate the feasibility, toxicity, and efficacy of the combination of paclitaxel, carboplatin, and long-term continuous infusion 5-fluorouracil (5-FU) in the treatment of advanced squamous carcinomas of va
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac4e3d2decdd29094e483ea95cb9eb74
https://doi.org/10.1002/1097-0142(20010801)92:3<642::aid-cncr1365>3.0.co
https://doi.org/10.1002/1097-0142(20010801)92:3<642::aid-cncr1365>3.0.co
Autor:
Joan B. Erland, Lisa H. Morrissey, Steven W. Smith, F. Anthony Greco, David Rinaldi, Howard A. Burris, John D. Hainsworth, J. R. Gray, Charles Dobbs, Sharlene Litchy, Eric L. Raefsky
Publikováno v:
Cancer. 92:2142-2147
BACKGROUND The objective of this study was to determine the feasibility and toxicity of paclitaxel and carboplatin given in the adjuvant setting alone for patients with resected Stage IB disease and combined with radiotherapy for patients with resect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c0964614e1cdad47a281a69b1c35213
https://doi.org/10.1002/1097-0142(20011015)92:8<2142::aid-cncr1556>3.0.co
https://doi.org/10.1002/1097-0142(20011015)92:8<2142::aid-cncr1556>3.0.co
Autor:
Lisa H. Morrissey, John D. Hainsworth, Sharlene Litchy, John H. Barton, Howard A. Burris, James E. Bradof, F. Anthony Greco
Publikováno v:
Cancer. 89:328-333
BACKGROUND Weekly administration of docetaxel was found to reduce myelosuppression and other nonhematologic toxicities when compared with administration every 3 weeks. In the current Phase II trial, the authors evaluated the feasibility, toxicity, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c55d389bd727d5831d33ff47111e119f
https://doi.org/10.1002/1097-0142(20000715)89:2<328::aid-cncr17>3.0.co
https://doi.org/10.1002/1097-0142(20000715)89:2<328::aid-cncr17>3.0.co
Autor:
Sharlene Litchy, F. Anthony Greco, Daniel C. Scullin, Paul Richards, John D. Hainsworth, Lisa H. Morrissey, Howard A. Burris, James D. Bearden
Publikováno v:
Blood. 95:3052-3056
Rituximab, a chimeric antibody that targets CD20+ B cells, produces a 48% response rate in patients with refractory low-grade non-Hodgkin lymphoma. In this phase II trial, patients with low-grade non-Hodgkin lymphoma who had previously received no sy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::233aa0db3d75de68925b577cda4d919a
https://doi.org/10.1182/blood.v95.10.3052.010k30_3052_3056
https://doi.org/10.1182/blood.v95.10.3052.010k30_3052_3056
Autor:
Jeremy K. Hon, L A Kalman, Daniel C. Scullin, Howard A. Burris, A. A. Meluch, Joan B. Erland, John D. Hainsworth, Steven W. Smith, Lisa H. Morrissey, F. Anthony Greco
Publikováno v:
Cancer. 85:1269-1276
BACKGROUND The combination of paclitaxel and carboplatin is widely used in the treatment of patients with advanced nonsmall cell lung carcinoma. In this Phase I/II study the authors evaluated the feasibility, toxicity, and efficacy of adding a third
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::491b2039e20cfae61de4ec6869a7c2fd
https://doi.org/10.1002/(sici)1097-0142(19990315)85:6<1269::aid-cncr8>3.0.co
https://doi.org/10.1002/(sici)1097-0142(19990315)85:6<1269::aid-cncr8>3.0.co